Webb29 okt. 2024 · Certain Warrants of Salarius Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-OCT-2024. These Warrants will be under lockup for 91 days … WebbSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. CEO David J. Arthur Employees 12 Headquarters Houston, Texas Founded 2014
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
WebbAbout SLRX Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. … Webb24 mars 2024 · SLRX ($2.11) is significantly undervalued by 78.01% relative to our estimate of its Fair Value price of $9.59 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety Significantly Below Fair Value Valuation SLRX is unprofitable, so we... subscribe to Premium to read more. dvd cd mp3 players
Certain Warrants of Salarius Pharmaceuticals, Inc. are subject to a ...
Webb10 juni 2024 · Salarius Pharmaceuticals ( NASDAQ: SLRX) on Friday filed for resale of up to ~7M shares by selling stockholders, issuable on exercise of certain outstanding … Webb6 apr. 2024 · Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) stock closed at 1.45 per share at the end of the most recent trading day (a 0.26 % change compared to the prior day closing price) with a volume of 31.69K shares and market capitalization of 3.58M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in … WebbSalarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need... U.S.... in balance tai chi brewster